Company intelligence / Profile preview

Ternary Therapeutics

London, England, United Kingdomternarytx.co.uk ↗

Ownership: Private
Development stage: Preclinical

Overview

Ternary Therapeutics ("TernaryTx") is a London-based biotech startup pioneering the rational design of molecular glues using advanced AI/ML platforms. The company focuses on immunology indications with a pipeline of novel degraders and activators targeting previously undruggable proteins. Their approach leverages proprietary computational tools to identify binding sites and facilitate ternary complex formation. As of May 2025, their programs are preclinical with no disclosed clinical results yet.

Therapeutic areas: Immunology
Modalities: Molecular glues (degraders and activators)Targeted protein degradation/activation
Industry: Biotech

Beyond the preview

Go deeper on Ternary Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ternary Therapeutics.

Explore the full profile